AnchorDx, a China-based developer of cancer early detection solutions, announced on Wednesday that it has enrolled its first patient in the UriFind bladder cancer assay clinical trial in the United States.
The more than 1,000-patient multi-centre, prospective registration study is intended to assess the performance of the non-invasive, quantitative real-time PCR (qPCR) assay aimed at detecting two DNA methylation biomarkers in urine specimens from subjects suspected of having bladder cancer.
The United States Food and Drug Administration (FDA) granted a Breakthrough Device Designation (BTD) for the assay in July 2021. Outcomes of this clinical trial are intended to meet the needs for an application for a Premarketing Approval (PMA) to the FDA in the United States. The trial is likely to include around 10 sites of Urology clinics and three CAP/CLIA laboratories.
L&T Technology Services plans to revolutionise medical imaging in collaboration with NVIDIA
Eli Lilly to build new high-tech manufacturing site in Germany
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Zymo Research's SafeCollect Saliva Collection Kit receives US FDA approval
Kanabo Group extends contract with major UK retailer
Biodesix enhances Nodify Lung testing with Tasso+ blood draw method
Byotrol unveils PROCESSUS instrument decontamination system
Integrum plans FDA PMA submission for OPRA in transhumeral amputations
Telix and Mauna Kea Technologies expand collaboration in urologic oncology surgery
Egetis secures exclusive licence agreement with Fujimoto for Emcitate development in Japan
KDx Diagnostics enters into strategic collaborations with leading distributors in Europe
Aplos Medical claims major GERD treatment milestone
Creo Medical receives US FDA clearance for Speedboat UltraSlim endoscopy device